<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00392080</url>
  </required_header>
  <id_info>
    <org_study_id>A5231018</org_study_id>
    <nct_id>NCT00392080</nct_id>
  </id_info>
  <brief_title>A Study Of The Effect Of CJ-023,423 On The Incidence Of Stomach Ulcers</brief_title>
  <official_title>A Multicenter, Randomized, Placebo And Active-Controlled Study Of The Effect Of CJ-023,423 On The Incidence Gastroduodenal Endoscopic Ulcers In Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      CJ-023,423 is a new medication being developed as an anti-inflammatory agent for the
      treatment of the signs and symptoms of osteoarthritis (OA). The purpose of this study is to
      evaluate whether patients treated with CJ-023,423 for 7 days (14 doses) have fewer
      gastrointestinal ulcers compared to patients treated with naproxen and placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint is the presence of gastroduodenal ulcers in each subject, as determined by a UGI endoscopy at the end of the treatment</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent, all-causality GI body system adverse events</measure>
    <time_frame>Duration of trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Dyspepsia Assessment (SODA)</measure>
    <time_frame>Duration of trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post treatment gastric, duodenal and gastroduodenal endoscopic scores (according to the mucosal grading scale). The gastroduodenal score is defined as the higher of the gastric and duodenal scores.</measure>
    <time_frame>Duration of trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of any gastric ulcer</measure>
    <time_frame>Duration of trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of any duodenal ulcer</measure>
    <time_frame>Duration of trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of any gastroduodenal erosion or ulcer</measure>
    <time_frame>Duration of trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of any gastric erosion or ulcer</measure>
    <time_frame>Duration of trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of any duodenal erosion or ulcer</measure>
    <time_frame>Duration of trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of any esophageal ulcer using the traditional grading method of: normal, erosion or ulcer</measure>
    <time_frame>Duration of trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of any esophageal ulcer or erosion using the LA classification: esophageal ulcers and erosions method with a Grade A, B, C, or D)</measure>
    <time_frame>Duration of trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of gastroduodenal ulcers in each subject</measure>
    <time_frame>Duration of trial</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">340</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>75 mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CJ-023,423</intervention_name>
    <description>75 mg BID</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>naproxen</intervention_name>
    <description>naproxen</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Is a healthy adult 18 to 75 years of age, inclusive; healthy is defined as no
             clinically relevant abnormalities identified as detailed medical history, full
             physical examination, including blood pressure [BP] and pulse rate [PR]measurement,
             12-lead electrocardiogram [ECG], and clinical safety laboratory tests

          -  If female and of childbearing potential (includes women who have been postmenopausal
             for &lt; 2 years ), must be using adequate contraception, must not be lactating and must
             have had a negative serum pregnancy test at Screening and a negative urine pregnancy
             test result within 24 hours prior to receiving study drug. The site investigator must
             ensure that female subjects are not pregnant prior to receiving the first dose of
             drug;

        Exclusion Criteria:

          -  Endoscopic evidence of inflammation, ulceration, erosion, petechiae, or active
             bleeding in the esophagus, stomach, pyloric channel, or duodenum at the baseline/
             randomization (Day 1) endoscopy (Mucosal Grading Scale score &gt;0);

          -  Active GI disease (e.g. inflammatory bowel disease), a history of gastroduodenal
             ulcers or bleeding, or a history of any gastric or duodenal surgery;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103-6204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <zip>33458</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ocoee</city>
        <state>Florida</state>
        <zip>34761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chesapeake</city>
        <state>Virginia</state>
        <zip>23320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A5231018&amp;StudyName=A%20Study%20Of%20The%20Effect%20Of%20CJ-023%2C423%20On%20The%20Incidence%20Of%20Stomach%20Ulcers</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2006</study_first_submitted>
  <study_first_submitted_qc>October 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2006</study_first_posted>
  <last_update_submitted>March 18, 2008</last_update_submitted>
  <last_update_submitted_qc>March 18, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2008</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naproxen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

